Mylan And Biocon Launch Semglee Insulin Glargine In US
Seeking Biosimilar Status And Interchangeability Designation For Lantus Rival
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
